Top

Published in:

01-11-2018 | Endocrine Surgery

The role of E and N-cadherin in the postoperative course of gonadotroph pituitary tumours

Authors: Kristin Astrid Berland Øystese, Jens Petter Berg, Kjersti Ringvoll Normann, Manuela Zucknick, Olivera Casar-Borota, Jens Bollerslev

Published in: Endocrine | Issue 2/2018

Abstract

Purpose

Gonadotroph tumours are the most abundant of the clinically silent pituitary tumours. There is a lack of reliable prognostic markers predicting their clinical course. Our aim was to determine the level of E-cadherin and N-cadherin in a cohort of clinically silent gonadotroph pituitary tumours, and compare them to the rate of reintervention.

Methods

Tumour tissue from primary surgery was retrospectively investigated and compared with clinical data. Immunohistochemical (N = 105) and real time-qPCR (N = 85) analyses for the levels of N-cadherin and the extra- and intracellular domains of E-cadherin were performed. The immunoreactive scores (IRS) and mRNA relative quantity were compared to the rate of reintervention.

Results

The tumours presented a high IRS for N-cadherin (Median 12 (IQR 12-12)) and almost no immunoreactivity for the extracellular domain of E-cadherin (Median 0 (IQR 0-0)). The membranous staining for the intracellular domain of E-cadherin varied (Median 6 (IQR 4-6). Reduced membranous expression of the intracellular domain of E-cadherin was associated with nuclear presence of the same domain. Nuclear staining for the intracellular domain of E-cadherin was associated with a lower rate of reintervention (p = 0.01).

Conclusion

We found that silent gonadotroph tumours presented high IRS for N-cadherin and low IRS for the extracellular domain of E-cadherin. A substantial proportion of the tumours presented nuclear staining for the intracellular domain of E-cadherin, accompanied by a reduced membranous expression of the intracellular domain of E-cadherin. Absence of nuclear staining for the intracellular domain of E-cadherin served as an independent predictor of reintervention.

Available only for authorised users

S.L. Asa, O. Casar-Borota, P. Chanson, E. Delgrange, P. Earls, S. Ezzat, A. Grossman, H. Ikeda, N. Inoshita, N. Karavitaki, M. Korbonits, E.R. Laws Jr., M.B. Lopes, N. Maartens, I.E. McCutcheon, O. Mete, H. Nishioka, G. Raverot, F. Roncaroli, W. Saeger, L.V. Syro, A. Vasiljevic, C. Villa, A. Wierinckx, J. Trouillas, From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocr. Relat. Cancer 24(4), C5–c8 (2017). https://doi.org/10.1530/erc-17-0004 CrossRefPubMed

T.A. Dolecek, J.M. Propp, N.E. Stroup, C. Kruchko, CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro. Oncol. 14(Suppl 5), v1–v49 (2012). https://doi.org/10.1093/neuonc/nos218 CrossRefPubMedPubMedCentral

S. Ezzat, S.L. Asa, W.T. Couldwell, C.E. Barr, W.E. Dodge, M.L. Vance, I.E. McCutcheon, The prevalence of pituitary adenomas: a systematic review. Cancer 101(3), 613–619 (2004). https://doi.org/10.1002/cncr.20412 CrossRef

A. Tjornstrand, K. Gunnarsson, M. Evert, E. Holmberg, O. Ragnarsson, T. Rosen, H. Filipsson Nystrom, The incidence rate of pituitary adenomas in western Sweden for the period 2001-2011. Eur. J. Endocrinol. / Eur. Fed. Endocr. Soc. 171(4), 519–526 (2014). https://doi.org/10.1530/eje-14-0144 CrossRef

T.T. Agustsson, T. Baldvinsdottir, J.G. Jonasson, E. Olafsdottir, V. Steinthorsdottir, G. Sigurdsson, A.V. Thorsson, P.V. Carroll, M. Korbonits, R. Benediktsson, The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study. Eur. J. Endocrinol. / Eur. Fed. Endocr. Soc. 173(5), 655–664 (2015). https://doi.org/10.1530/eje-15-0189 CrossRef

E. Ferrante, M. Ferraroni, T. Castrignano, L. Menicatti, M. Anagni, G. Reimondo, P. Del Monte, D. Bernasconi, P. Loli, M. Faustini-Fustini, G. Borretta, M. Terzolo, M. Losa, A. Morabito, A. Spada, P. Beck-Peccoz, A.G. Lania, Non-functioning pituitary adenoma database: a useful resource to improve the clinical management of pituitary tumors. Eur. J. Endocrinol. / Eur. Fed. Endocr. Soc. 155(6), 823–829 (2006). https://doi.org/10.1530/eje.1.02298 CrossRef

A. Di Ieva, F. Rotondo, L.V. Syro, M.D. Cusimano, K. Kovacs, Aggressive pituitary adenomas—diagnosis and emerging treatments. Nat. Rev. Endocrinol. 10(7), 423–435 (2014). https://doi.org/10.1038/nrendo.2014.64 CrossRefPubMed

O. Mete, S.L. Asa, Clinicopathological correlations in pituitary adenomas. Brain Pathol. 22(4), 443–453 (2012). https://doi.org/10.1111/j.1750-3639.2012.00599.x CrossRefPubMed

S.L. Asa, A.M. Bamberger, B. Cao, M. Wong, K.L. Parker, S. Ezzat, The transcription activator steroidogenic factor-1 is preferentially expressed in the human pituitary gonadotroph. J. Clin. Endocrinol. Metab. 81(6), 2165–2170 (1996). https://doi.org/10.1210/jcem.81.6.8964846 CrossRefPubMed

10.

M. Guarino, B. Rubino, G. Ballabio, The role of epithelial-mesenchymal transition in cancer pathology. Pathology 39(3), 305–318 (2007). https://doi.org/10.1080/00313020701329914 CrossRefPubMed

11.

M. Diepenbruck, G. Christofori, Epithelial-mesenchymal transition (EMT) and metastasis: yes, no, maybe? Curr. Opin. Cell Biol. 43, 7–13 (2016). https://doi.org/10.1016/j.ceb.2016.06.002 CrossRefPubMed

12.

E.C. Ferber, M. Kajita, A. Wadlow, L. Tobiansky, C. Niessen, H. Ariga, J. Daniel, Y. Fujita, A role for the cleaved cytoplasmic domain of E-cadherin in the nucleus. J. Biol. Chem. 283(19), 12691–12700 (2008). https://doi.org/10.1074/jbc.M708887200 CrossRefPubMedPubMedCentral

13.

M.J. Wheelock, Y. Shintani, M. Maeda, Y. Fukumoto, K.R. Johnson, Cadherin switching. J. Cell. Sci. 121, 727–735 (2008). https://doi.org/10.1242/jcs.000455 CrossRefPubMed

14.

B. Tsuchiya, Y. Sato, T. Kameya, I. Okayasu, K. Mukai, Differential expression of N-cadherin and E-cadherin in normal human tissues. Arch. Histol. Cytol. 69(2), 135–145 (2006)CrossRef

15.

S. Yamada, K. Ohyama, M. Taguchi, A. Takeshita, K. Morita, K. Takano, T. Sano, A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas. Neurosurgery 61, 580–584 (2007). https://doi.org/10.1227/01.neu.0000290906.53685.79. discussion 584-585CrossRefPubMed

16.

W. Zhou, Y. Song, H. Xu, K. Zhou, W. Zhang, J. Chen, M. Qin, H. Yi, J.A. Gustafsson, H. Yang, X. Fan, In nonfunctional pituitary adenomas, estrogen receptors and slug contribute to development of invasiveness. J. Clin. Endocrinol. Metab. 96(8), E1237–E1245 (2011). https://doi.org/10.1210/jc.2010-3040 CrossRefPubMed

17.

M.S. Elston, A.J. Gill, J.V. Conaglen, A. Clarkson, R.J. Cook, N.S. Little, B.G. Robinson, R.J. Clifton-Bligh, K.L. McDonald, Nuclear accumulation of e-cadherin correlates with loss of cytoplasmic membrane staining and invasion in pituitary adenomas. J. Clin. Endocrinol. Metab. 94(4), 1436–1442 (2009). https://doi.org/10.1210/jc.2008-2075 CrossRefPubMed

18.

J. Torhorst, C. Bucher, J. Kononen, P. Haas, M. Zuber, O.R. Kochli, F. Mross, H. Dieterich, H. Moch, M. Mihatsch, O.P. Kallioniemi, G. Sauter, Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am. J. Pathol. 159(6), 2249–2256 (2001). https://doi.org/10.1016/s0002-9440(10)63075-1 CrossRefPubMedPubMedCentral

19.

O. Casar-Borota, S.L. Fougner, J. Bollerslev, J.M. Nesland, KIT protein expression and mutational status of KIT gene in pituitary adenomas. Virchows Arch. 460(2), 171–181 (2012). https://doi.org/10.1007/s00428-011-1185-8 CrossRefPubMed

20.

O. Casar-Borota, K.A. Oystese, M. Sundstrom, L. Melchior, V. Popovic, A high-throughput analysis of the IDH1(R132H) protein expression in pituitary adenomas. Pituitary 19, 407–14 (2016). https://doi.org/10.1007/s11102-016-0720-7 CrossRefPubMed

21.

O. Casar-Borota, A. Heck, S. Schulz, J.M. Nesland, J. Ramm-Pettersen, T. Lekva, I. Alafuzoff, J. Bollerslev, Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide. J. Clin. Endocrinol. Metab. 98(11), E1730–E1739 (2013). https://doi.org/10.1210/jc.2013-2145 CrossRefPubMed

22.

W. Remmele, H.E. Stegner, [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Der Pathol. 8(3), 138–140 (1987)

23.

M. Lee, A. Lupp, N. Mendoza, N. Martin, R. Beschorner, J. Honegger, J. Schlegel, T. Shively, E. Pulz, S. Schulz, F. Roncaroli, N.S. Pellegata, SSTR3 is a putative target for the medical treatment of gonadotroph adenomas of the pituitary. Endocr. Relat. Cancer 22(1), 111–119 (2015). https://doi.org/10.1530/erc-14-0472 CrossRefPubMed

24.

K.A. Oystese, O. Casar-Borota, K.R. Normann, M. Zucknick, J.P. Berg, J. Bollerslev, Estrogen receptor alpha, a sex-dependent predictor of aggressiveness in nonfunctioning pituitary adenomas: SSTR and sex hormone receptor distribution in NFPA. J. Clin. Endocrinol. Metab. 102(9), 3581–3590 (2017). https://doi.org/10.1210/jc.2017-00792 CrossRefPubMed

25.

K.R. Normann, K.A. Oystese, J.P. Berg, T. Lekva, J. Berg-Johnsen, J. Bollerslev, N.C. Olarescu, Selection and validation of reliable reference genes for RT-qPCR analysis in a large cohort of pituitary adenomas. Mol. Cell. Endocrinol. 437, 183–189 (2016). https://doi.org/10.1016/j.mce.2016.08.030 CrossRefPubMed

26.

N. Chauvet, N. Romano, A.C. Meunier, E. Galibert, P. Fontanaud, M.N. Mathieu, G. Osterstock, P. Osterstock, E. Baccino, V. Rigau, H. Loiseau, S. Bouillot-Eimer, A. Barlier, P. Mollard, N. Coutry, Combining cadherin expression with molecular markers discriminates invasiveness in growth hormone and prolactin pituitary adenomas. J. Neuroendocrinol. 28(2), 12352 (2016). https://doi.org/10.1111/jne.12352 CrossRefPubMed

27.

S. Ezzat, L. Zheng, D. Winer, S.L. Asa, Targeting N-cadherin through fibroblast growth factor receptor-4: distinct pathogenetic and therapeutic implications. Mol. Endocrinol. (Baltim., Md.) 20(11), 2965–2975 (2006). https://doi.org/10.1210/me.2006-0223 CrossRef

28.

D. Greenbaum, C. Colangelo, K. Williams, M. Gerstein, Comparing protein abundance and mRNA expression levels on a genomic scale. Genome Biol. 4(9), 117 (2003). https://doi.org/10.1186/gb-2003-4-9-117 CrossRefPubMedPubMedCentral

29.

G. Berx, F. van Roy, Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb. Perspect. Biol. 1, a003129 (2009). https://doi.org/10.1101/cshperspect.a003129 CrossRefPubMedPubMedCentral

30.

R.B. Hazan, G.R. Phillips, R.F. Qiao, L. Norton, S.A. Aaronson, Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J. Cell. Biol. 148(4), 779–790 (2000)CrossRef

31.

M.T. Nieman, R.S. Prudoff, K.R. Johnson, M.J. Wheelock, N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. J. Cell. Biol. 147(3), 631–644 (1999)CrossRef

32.

L.D. Derycke, M.E. Bracke, N-cadherin in the spotlight of cell-cell adhesion, differentiation, embryogenesis, invasion and signalling. Int. J. Dev. Biol. 48(5-6), 463–476 (2004). https://doi.org/10.1387/ijdb.041793ld CrossRefPubMed

33.

W. Jia, J. Zhu, T.A. Martin, A. Jiang, A.J. Sanders, W.G. Jiang, E.M.T. Epithelial-mesenchymal Transition, Markers in human pituitary adenomas indicate a clinical course. Anticancer Res. 35(5), 2635–2643 (2015)PubMed

34.

S.L. Fougner, T. Lekva, O.C. Borota, J.K. Hald, J. Bollerslev, J.P. Berg, The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response. J. Clin. Endocrinol. Metab. 95(5), 2334–2342 (2010). https://doi.org/10.1210/jc.2009-2197 CrossRefPubMed

35.

J.A. Evang, J.P. Berg, O. Casar-Borota, T. Lekva, M.K. Kringen, J. Ramm-Pettersen, J. Bollerslev, Reduced levels of E-cadherin correlate with progression of corticotroph pituitary tumours. Clin. Endocrinol. 75(6), 811–818 (2011). https://doi.org/10.1111/j.1365-2265.2011.04109.x CrossRef

36.

K. Ito, I. Okamoto, N. Araki, Y. Kawano, M. Nakao, S. Fujiyama, K. Tomita, T. Mimori, H. Saya, Calcium influx triggers the sequential proteolysis of extracellular and cytoplasmic domains of E-cadherin, leading to loss of beta-catenin from cell-cell contacts. Oncogene 18(50), 7080–7090 (1999). https://doi.org/10.1038/sj.onc.1203191 CrossRefPubMed

37.

S.L. Fougner, O. Casar-Borota, A. Heck, J.P. Berg, J. Bollerslev, Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin. Endocrinol. 76(1), 96–102 (2012). https://doi.org/10.1111/j.1365-2265.2011.04163.x CrossRef

38.

P. Bouris, S.S. Skandalis, Z. Piperigkou, N. Afratis, K. Karamanou, A.J. Aletras, A. Moustakas, A.D. Theocharis, N.K. Karamanos, Estrogen receptor alpha mediates epithelial to mesenchymal transition, expression of specific matrix effectors and functional properties of breast cancer cells. Matrix biology: journal of the International Society for. Matrix Biol. 43, 42–60 (2015). https://doi.org/10.1016/j.matbio.2015.02.008 CrossRefPubMed

39.

S.H. Park, L.W. Cheung, A.S. Wong, P.C. Leung, Estrogen regulates Snail and Slug in the down-regulation of E-cadherin and induces metastatic potential of ovarian cancer cells through estrogen receptor alpha. Mol. Endocrinol. 22(9), 2085–2098 (2008). https://doi.org/10.1210/me.2007-0512 CrossRefPubMedPubMedCentral

40.

J.H. Kim, J.H. Lee, J.H. Lee, A.R. Hong, Y.J. Kim, Y.H. Kim, Endoscopic transsphenoidal surgery outcomes in 331 nonfunctioning pituitary adenoma cases after a single surgeon learning curve. World Neurosurg. 109, e409–e416 (2017). https://doi.org/10.1016/j.wneu.2017.09.194 CrossRefPubMed

41.

Y. Chen, C.D. Wang, Z.P. Su, Y.X. Chen, L. Cai, Q.C. Zhuge, Z.B. Wu, Natural history of postoperative nonfunctioning pituitary adenomas: a systematic review and meta-analysis. Neuroendocrinology 96(4), 333–342 (2012). https://doi.org/10.1159/000339823 CrossRefPubMed

42.

L.J. Lewis-Tuffin, F. Rodriguez, C. Giannini, B. Scheithauer, B.M. Necela, J.N. Sarkaria, P.Z. Anastasiadis, Misregulated E-cadherin expression associated with an aggressive brain tumor phenotype. PLoS. One. 5, e13665 (2010). https://doi.org/10.1371/journal.pone.0013665 CrossRefPubMedPubMedCentral

43.

U. Steinhusen, J. Weiske, V. Badock, R. Tauber, K. Bommert, O. Huber, Cleavage and shedding of E-cadherin after induction of apoptosis. J. Biol. Chem. 276(7), 4972–4980 (2001). https://doi.org/10.1074/jbc.M006102200 CrossRefPubMed

44.

M. Rosner, M. Hengstschlager, Letter to the Editor: human pluripotent stem cells release oncogenic soluble E-cadherin. Stem Cells 34(9), 2443–2446 (2016). https://doi.org/10.1002/stem.2461 CrossRefPubMed

Title: The role of E and N-cadherin in the postoperative course of gonadotroph pituitary tumours
Authors: Kristin Astrid Berland Øystese
Jens Petter Berg
Kjersti Ringvoll Normann
Manuela Zucknick
Olivera Casar-Borota
Jens Bollerslev
Publication date: 01-11-2018
Publisher: Springer US
Published in: Endocrine / Issue 2/2018
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-018-1679-0

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The role of E and N-cadherin in the postoperative course of gonadotroph pituitary tumours

Abstract

Purpose

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2018

Sentinel lymph node biopsy in small papillary thyroid cancer. A review on novel surgical techniques

Macroprolactinomas: longitudinal assessment of biochemical and imaging therapeutic responses

Predictors of surgical outcome and early criteria of remission in acromegaly—some controversial issues

Thyroid Cancer Epidemiology in South Spain: a population-based time trend study

Cabergoline for the treatment of bromocriptine-resistant invasive giant prolactinomas

An assessment of the relationship between thyroid nodule characteristics, insulin resistance and arterial stiffness in euthyroid nodular goiter

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page